Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The French Public Health Council recommended pneumococcal vaccination combined strategy for
all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent
pneumococcal injection followed 2 months later by polysaccharide 23-valent vaccine injection.
General practitioners are usually in charge of this vaccination. Conjugated pneumococcal
vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and
lymphoma are treated with multiple courses of chemotherapy, impairing the immune system and
potentially the response to vaccination. These patients are more at risk for developing
pneumococcal invasive diseases than the general population. However, efficacy of pneumococcal
vaccination is poorly documented in this setting. We assume that 70% of the patients are
non-responders to vaccination, according to their anti-pneumococcal immunoglobulin G titers
and the opsonophagocytic activity. To assess the immunogenicity of the pneumococcal
vaccination combined strategy in adult population of acute leukemia and lymphoma, the
investigator will measure anti-pneumococcal serotype-specific immunoglobulin G titers and
opsonophagocytic activity at different time-points after completion of the combined vaccine
strategy. The primary objective is to assess the immunogenicity of pneumococcal vaccination
combined strategy at 3 months after the 13-valent pneumococcal injection (corresponding to 1
month after the end of the combined strategy) using immunoglobulin G titers and
opsonophagocytic activity. At different time points (day 0, 1 month after the 13-valent
pneumococcal injection, the day of the injection of the polysaccharide 23-valent vaccine, one
month after the injection of the polysaccharide 23-valent vaccine, 3-6 months after the
polysaccharide 23-valent vaccine,9-12 months after the polysaccharide 23-valent vaccine), the
immunological response to vaccination will be monitored using specific-serotype
immunoglobulin G titers, opsonophagocytic activity, and total anti-pneumococcal
Immunoglobulin. The investigator will determine predictive factors of non-response to
vaccination by comparing demographic data, biological data and treatment received by both
acute myeloblastic leukemia and lymphoma patients. The tolerance and safety of the
vaccination strategy will also be assessed in this specific hematological population.